Lowell L. Hart, MD, FACP | Authors


EP. 4A: The Role of Trilaciclib in the Management of Chemotherapy-Induced Myelosuppression in SCLC

December 22, 2021

In the second interview of the series, Dr. Lowell L. Hart of Florida Cancer Specialists & Research Institute considers the impact of chemotherapy-induced myelosuppression in small cell lung cancer and examines how trilaciclib fits into the current treatment landscape.

Discussing the Benefits of Trilaciclib Plus Topotecan for Treatment of Extensive-stage SCLC

August 27, 2019

Lowell L. Hart, MD, FACP, scientific director of clinical research, Florida Cancer Specialists, and associate professor of medicine, Wake Forest University School of Medicine, discusses the effect of CDK4/6 inhibitor, trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Hart presented the phase II results from the blinded, multicenter study during the 2019 ASCO Annual Meeting.